overview

statement of need

Patent ductus arteriosus (PDA) is a common issue in preterm/low birth-weight infants. In babies who are less than 1500 g at birth, studies show that the incidence exceeds 30%. Although PDA is a common condition in the premature infant, the timing and mode of treatments continue to vary. After decades of research, health care professionals have been unable to agree on standardized guidelines for the management of PDA. The appropriate diagnosis and management of the condition can prevent morbidity and mortality. Therapeutic options include conservative treatment, surgery, and medication. Recently, a new formulation of intravenous ibuprofen has been approved by the United States Food and Drug Administration that may provide a new and potentially safer treatment approach.

This activity will provide an educational opportunity to learn about appropriate diagnosis, and the practical issues around medical management choices, that may impact patient outcomes.

The convenient on-demand webcast format of this program provides an opportunity for neonatologists, pediatricians, nurses, pharmacists and other health care professionals involved in the care of preterm infants to update their knowledge and learn about promising new alternatives to treating PDA based on their individual needs and schedules.